Biogen Considers Aduhelm Price Cut as Competing Alzheimer’s Drug Approved by FDA

Biogen and its partner Eisai released a statement regarding Alzheimer’s Drug Aduhelm, which is priced at $56,000 per year. The companies note that the price may come down, but only if certain conditions are met. Although the long-awaited Aduhelm was welcomed by patient groups, the FDA recently approved another Alzheimer’s drug, lecanemab. Aduhelm’s high price has faced widespread criticism and concern that Medicare would face substantial economic burden.

“The FDA has justified its decision to approve Aduhelm by opting for a conditional approval, which means it can be prescribed to patients while Biogen and Eisai carry out another clinical trial to back up its supposed effects in Alzheimer’s. The timeframe for completing that trial and filing the data is long though – nine years has been allowed by the FDA – which means Aduhelm could generate tens of billions of dollars in sales before it faces the risk of Aduhelm being withdrawn from sale.” Read more here.

(Source: Phil Taylor, Pharmaphorum, 6/24/21)